


What is Shingles?

Shingles is a serious disease caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox.¹



The Typical Symptoms of Shingles

- **Rash** – a painful, itchy rash often develops on one side of the body.²
- The **pain** associated with shingles is often described as burning, stabbing or shock-like, and it may be severe and accompanied by itching.^{1,3}
- The rash can last between **2-4 weeks**.³
- Even once the rash is gone, a person can experience **postherpetic neuralgia** (PHN) – pain that can last for months or years.³
- Up to 30% of patients experience PHN.⁴



The Aging Immune System and Vaccines

- Weakened immunity in older adults presents a continuing **challenge in adult vaccination**.⁵
- As we age, the ability of our immune system to mount a strong and effective response to infection declines meaning that **after the age of 50, a person's risk for shingles increases**.^{1,3}
- **Age-related decline in immunity** is recognized as an important risk factor for shingles.¹




The Facts About Shingles



One in three:
the estimated individual lifetime risk of developing shingles¹

>90%


The percentage of individuals over the age of 50 who have had chickenpox and are at risk for shingles⁶



The number of shingles cases that occur in individuals aged 50+⁷

~130,000

The estimated number of new shingles cases each year in Canada⁸



1. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008 Jun;57(RR-5):1-30.
 2. Lal et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. *N Engl J Med*. 2015; 372:2087-2096
 3. Johnson RW et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. *Therapeutic Advances in Vaccines*. 2015;3(4):109-120.
 4. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. *BMJ Open*. 2014 Jun;4(6):e004833.
 5. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. *J Infect Dis*. 2016 Jun;213(12):1872-5.
 6. National Advisory Committee on Immunization. Statement on the Recommended use of Herpes Zoster Vaccine. January 2010, 36(ASC-1):1-19.
 7. Bricout H, et al. Herpes zoster-associated mortality in Europe: a systematic review. *BMC Public Health*. 2015;15:466.
 8. Government of Canada. Page 8: Canadian Immunization Guide: Part 4 - Active Vaccines. Available at: [https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-\(shingles\)-vaccine.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html). Last accessed: September 2017.